Hydrocodone Bitartrate
FDA-approved product (capsule, extended release, oral), marketed as Hydrocodone Bitartrate, Hysingla Er, Vantrela Er and 1 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cough
- Drug dependence
- Pain
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Natural opium alkaloids; Opium alkaloids and derivatives
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA44.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli36.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis36.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Hydrocodone Bitartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Role of Pregabalin in Treatment of Post-Op Pain in Fracture Patients
NCT00583869 · start 2007-05
Registered record
- Registry ID
- NCT00583869
- Conditions
- Post-operative Pain
- Interventions
- Placebo; Pregabalin; Pregabalin
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Completed
- Start
- 2007-05
- Completion
- 2009-08
- Enrolment
- 86
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPost-operative PainInterventionPlacebo; Pregabalin; PregabalinPhaseEarly phase 1Registry statusCompletedTrial Comparing Intravenous and Oral Moderate Sedation for First Trimester Surgical Abortions
NCT01011634 · start 2007-05
Registered record
- Registry ID
- NCT01011634
- Conditions
- Undesired Intrauterine Pregnancy; First Trimester Pregnancy
- Interventions
- Intravenous moderate sedation versus oral medication
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2007-05
- Completion
- 2008-11
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUndesired Intrauterine Pregnancy; First Trimester PregnancyInterventionIntravenous moderate sedation versus oral medicationPhasePhase 4Registry statusTerminatedA Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
NCT00314340 · start 2005-11
Registered record
- Registry ID
- NCT00314340
- Conditions
- Chronic Pain
- Interventions
- Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity; ER Morphine; hydrocodone plus acetaminophen; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-11
- Completion
- 2008-04
- Enrolment
- 12
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic PainInterventionMarkers of Abuse Liability, Neuropsych Testing, and Cue Reactivity; ER Morphine; hydrocodone plus acetaminophen; placeboPhasePhase 4Registry statusCompletedA Study Comparing the Analgesic Activity of Extended Release Hydrocodone/Acetaminophen (Vicodin® CR) and Placebo in Subjects With Pain Following Bunionectomy Surgery
NCT00404391 · start 2003-10
Registered record
- Registry ID
- NCT00404391
- Conditions
- Pain
- Interventions
- Hydrocodone/Acetaminophen Extended Release; Hydrocodone/Acetaminophen Extended Release; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-10
- Completion
- 2004-03
- Enrolment
- 210
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPainInterventionHydrocodone/Acetaminophen Extended Release; Hydrocodone/Acetaminophen Extended Release; PlaceboPhasePhase 2Registry statusCompletedA Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery
NCT02197156 · start 2002-08
Registered record
- Registry ID
- NCT02197156
- Conditions
- Postoperative Pain
- Interventions
- 10 mg HC-ER; 20 mg HC-ER; 30 mg HC-ER; 40 mg HC-ER; 10 mg HC / 325 mg APAP; Matching Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-08
- Completion
- 2003-02
- Enrolment
- 241
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPostoperative PainIntervention10 mg HC-ER; 20 mg HC-ER; 30 mg HC-ER; 40 mg HC-ER +2 morePhasePhase 2Registry statusCompleted